Background: Clinicians often use population-based reference intervals (RIs) when interpreting patient results. However, this method can present problems if the analyte in question has wide variability from person to person.
share in common, whereas other sources of variation may be due to differences between individuals. By comparing the test results from a patient with certain reference population values, it is possible to detect clinically relevant changes in blood biomarkers that can be useful for prevention, diagnosis, and treatment of various diseases.
Numerous factors can contribute to variations in blood markers. Some of the variables are controllable (blood collection technique), whereas other characteristics, such as ethnicity, sex, and age, are not subject to manipulation. Often, biological factors are the most important source of variation over time for certain analytes. For example, marked changes can occur during the neonatal period, childhood, puberty, menopause, and aging. Also, certain analytes have biological rhythms that can vary diurnally, monthly, or seasonally. 1 Interpretation of test results from a patient using the reference values of the testing laboratory is, thus far, the only valid tool available to clinicians when the biological DOI: 10.1093/labmed/lmy044 variability of the population reference values and of the target population are comparable. 2 Population-based reference values, despite their limitations, remain the most commonly used interpretative tool for clinicians to date.
Reference populations commonly use convenience sampling from readily available and cooperative groups, such as blood donors, laboratory personnel, or medical students. This practice is problematic for several reasons. First, there may be a selection bias in instances in which the reference population does not adequately represent the population ranges for that analyte. For example, the chosen reference population may be extremely healthy or have a higher prevalence of some pathological condition, which will result in a reference interval (RI) that is biased relative to the truly "healthy" range. Conclusions based on these biased intervals may result in increased false-positive or false-negative rates, respectively. Second, certain analytes display a high degree of interindividual variation as a result of widely ranging homeostatic set points, even within a population that is considered "healthy." This marked individuality makes it difficult to construct a single RI that represents a "healthy" range for all individuals because many subjects will present with values that are highly unique for them but are still within population-based reference value ranges. [3] [4] [5] [6] [7] [8] [9] [10] Repeated measurements of an analyte obtained by a longitudinal study of an individual may be preferable to use of a single measure in conjunction with population-based references. In the case of repeat measures, the patients have their own reference for each biomarker, and changes between results in consecutive tests may indicate illness. 2 Longitudinal assessment requires knowledge of the within-subject variability. Sufficient hematological or chemistry values in published data during a long period of time (many years) are not available for most laboratory analytes.
The aim of our study was to assess the effect of aging on commonly requested hematological parameters during a 30-year period while also examining the inter-and intraindividual biological variation for hematological laboratory markers in a population of white non-Hispanic males to evaluate the appropriateness of RIs in clinical settings.
We suggest, in some cases, that personalized baseline laboratory tests may be preferable to the population-based reference values for monitoring and follow-up of a patient. In this study, we explored the biological variation of white blood cells (WBCs), lymphocytes, monocytes, neutrophils, red blood cells (RBCs), hemoglobin (Hg), hematocrit (Hct), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH), mean corpuscular hemoglobin concentration (MCHC), and platelets (PLT).
Materials and Methods
We investigated the routine hematological markers of 82 participants with no diagnosis of major illness, such as cancer, hepatitis B and C, kidney problems, or diabetes, during a 30-year period. These individuals were men who have sex with men (MSM) participating in the Multicenter AIDS Cohort Study (MACS), who were documented to have human immunodeficiency virus (HIV)-1 seronegativity at every study visit and self-reported as white, non-Hispanic.
11
Each follow-up visit of each participant was monitored by reviewing his health questionnaire form, physical examination form, and laboratory test reports. Based on this information, if there was evidence of any acute illness, the blood-marker data for that participant for that visit was excluded from the data analysis. The lower reference level (LRL) and upper reference level (URL) in Figure 1 and Figure 2 are the calculated weighted mean of the LRL and URL of the aforementioned laboratories. CBC data were available for analysis from 4759 of 4920 (96.7%) of the overall expected individual visits.
Statistical Analysis
Descriptive statistics for the 11 hematological markers that comprised the complete blood count (absolute cell counts for WBC, RBC, PLT, lymphocytes, monocytes, neutrophils; Hb, Hct, MCV, MCH, and MCHC) were generated for mean and absolute ranges for CV G and CV I . Mixed models were used for repeated-measures analyses to identify trends during a 30-year period for each marker and the crosssectional effect of age on blood markers; the nested analysis of variance was used for calculation of coefficients of variation for CV I and CV G . CV I and CV G were calculated according to the approach used by Fraser and Harris.
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Because the precision of the measurement tools was high and the reliability of replicate measures was not of interest to us, we omitted measures of analytic variation from these calculations.
The index of individuality (II) is the simple ratio of the 2 biological components of variation, namely, intraindividual to interindividual, and is calculated using the formula CV I / CV G . 1 The II, as defined by Harris, 12 assesses the usefulness of population-based reference values for interpretation of laboratory tests: if the II of a given analyte is greater than 1.4, population-based intervals are appropriate; an II below 1.4 indicates decreased usefulness of population-based RIs. Analytes with a II less than 0.6 demonstrate a high degree of individuality, making individual-based RIs more useful.
All analysis was performed using SAS software, version 9.4 (SAS Institute, Inc). Graphs were created by using SigmaPlot software, version 13 (Systat Software, Inc).
Results
The CV I , CV G , and II, along with the overall means of hematologic parameters for 1 year (baseline, visit 1, and visit 2), 10 years (baseline to visit 19), 20 years (baseline to visit 39), and 30 years (baseline to visit 59) of follow-up, are presented in Table 1 . As described in the Materials and Methods section, it is considered appropriate to use population-based reference ranges when the II of a given analyte is greater than 1.4. 12 With the exception of MCHC at all 4 time intervals and monocytes at 10 years and 20 years of follow-up, the IIs in our study for the routine hematological markers were less than 1.4.
The means and absolute ranges (minimum-maximum values) during all study visits for each individual (n = 82) are shown graphically for WBCs, lymphocytes, monocytes, and neutrophils ( Figure 1) , as well as for RBCs, Hb, Hct, and PLT ( Figure 2 ). Visual assessment of these figures shows that although the mean values of the same analyte for individuals are clearly different from each other, most of the mean values lie within the RI. Looking at the data ranges, much of the data fall within the RIs; however, certain individuals have some data points outside the upper or lower reference limits (the laboratory reference values) or both. In 1 case, nearly all the data points for a participant were outside the RIs (ie, WBC and neutrophils; Figure 1 , subject 39).
To evaluate direction and magnitude of changes in each marker from baseline during the 30-year follow-up period, we used mixed modeling via SAS software to estimate the average changes in values per year or interval and the corresponding P value ( Table 2) . The longitudinal analysis during the course of 30 years showed a statistically significant decrease for the directly measured hematologic markers WBCs, RBCs, Hg, and PLT. Other markers that also showed significant decreases were Hct (which is calculated using the equation RBC × MCV) and absolute neutrophil count (calculated using the equation WBC × % neutrophils in automated 3-part WBC differential).
We observed an increase for MCV, which is directly measured in automated hematology analyzers. This finding suggests that the decreases in Hct were due to a relatively greater decrease in RBC count, compared with the increases in MCV. Similarly, MCH (calculated from Hb/ RBC) showed an increase, suggesting that the RBC count was also relatively more decreased than the Hg concentration. The absolute monocyte count (WBC × % monocytes) also increased, despite the concomitant decrease in total WBC count, which suggests that the percentage of monocytes was increasing even more than was evident from the absolute numbers. We observed no significant change over time for MCHC (Hb/RBC × MCV), which is calculated from 3 different RBC-related measurements moving in different directions, nor any for absolute lymphocyte count (WBC × % lymphocytes). There were no cross-sectional effects of age on the tested blood markers (P> .05). 
Figure 1
Data points for study participants regarding white blood cells (WBCs), lymphocytes, monocytes, and neutrophils, including lower and upper reference levels, as well as means and absolute ranges, for each individual during the 30-year study period.
Discussion
Clinical laboratory tests and population-based RIs are used for interpreting laboratory test results for diagnosis, case finding, screening, and monitoring the health of patients during treatment. Also, serial testing of patients can assist clinicians in detecting changes over time.
Ideally, a dedicated hematology analyzer and a single laboratory would be used for blood analysis for the entire length of the study (30 years); however, this desired end was unattainable. A limitation in our study is the use of different laboratories (due to certain laboratories having been bought out by competing laboratories) or different instruments (due to upgraded models and technology advances) for measurement of blood markers during the 30-year course of the study. Based on our knowledge of the comparability of blood counts between the Coulter Ac•T Diff (Beckman Coulter, Inc) and Sysmex XT-1800i (Sysmex Corporation) hematology analyzers, as well as CLIA restrictions and DOI: 10.1093/labmed/lmy044 requirements on clinical laboratories, the switching of clinical laboratories or hematological instruments during the course of the study should have had a minimal, but not significant, impact on the final analyses of our data.
We have longitudinally examined the extent of biological variation in routine circulating blood markers measured in a relatively homogeneous cohort of men as they aged during a 30-year period and assessed data for a number of hematological parameters in the serial results of individuals. The ability to evaluate as many as 60 observations per person during the 30-year interval provided us a unique opportunity to generate individual mean and ranges of blood markers (Figures 1 and 2 ). These figures show many occurrences in which the value of a test result may be very unusual for a particular individual (ie, extends the minimum or maximum of the range dramatically, relative to the mean) but is still within the conventional population-based RI. In these circumstances, in which a value is clearly out of the ordinary for a specific individual but is not flagged as "abnormal" according to population-based reference ranges, the reference values may become unreliable and may mask biologically or clinically important changes.
We recognize that our study population may limit the generalizability of our observations. However, a strength of our study is that it includes a single-sex, single-ethnicity population, which maximizes our ability to evaluate biological variation over time.
Numerous other investigators have studied the source of biological variation of hematologic markers on a daily, weekly, or monthly basis and, in one instance, for 3 visits during a 10-year period. 13 We are unaware, however, of any published study that is as intensive (twice a year), extended (during 3 decades), and longitudinal as the study we have presented herein.
We expect to observe disagreement in variation values due to differences in participant population restrictions, along with frequency and duration of follow-up. With the 
Figure 2
Data points for study participants regarding red blood cells (RBCs), hemoglobin (Hg), hematocrit (Hct), and platelets (PLT), including lower and upper reference levels, as well as means and absolute ranges, for each individual during the 30-year study period. exception of MCHC, monocyte, and neutrophils, our data show some similarity with published data, such as lower CV I and higher CV G .
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As early as 1935, Miller et al 14 observed a decrease in RBC count and Hg and no changes for WBC and differential counts (cross-sectional) in a population of elderly individuals, compared with younger adults. Our longitudinal data showed similar statistically significant decreases in RBC count and Hg (g/dL), as well as Hct (%) but, in contrast with the results of earlier studies, a decrease in the total WBC and neutrophils, as participants aged during a 30-year period. It is impossible to determine whether these differences are attributable to study design (cross-sectional vs longitudinal), study populations, and/or the technology in use at the time.
Statland et al 15 studied physiologic variation of hour-to-hour, day-to-day, and week-to week changes of hematological parameters during a 4-week period. Comparing their weekto-week data to ours, the CV I reported in the Statland study findings is smaller than ours, which may be attributed to the shorter (4 weeks for Statland et al) versus longer (30 years for our study) follow-up period. In contrast, their CV G data values were greater, compared with those from our study results, which could be due to differences in sex and ethnicity among their 20 subjects versus the 82 white non-Hispanic male participants in our study.
In a cross-sectional study, MacKinney 16 observed a significant age-dependent decline in absolute lymphocyte count. This decline appeared to be in 3 phases, namely, a precipitous drop from birth to age 20 years, a stationary phase for 3 decades (ages 20-50 years), and accelerating decline up to age 90 years.
Sparrow et al 13 longitudinally evaluated peripheral lymphocyte count in men of 3 age groups (23-44 years, 45-54 years, and 55 + years) for 3 visits during an average period of 10 years. The researchers found that the 3 age cohorts did not have significantly different lymphocyte counts; when those groups were followed during a 10-year period (the older participant was 70 years), no significant differences were observed.
When we applied the mixed model for each marker, we found that with the exception of MCHC and lymphocytes, there are longitudinal effects of aging (P < .05); however, there was no cross-sectional effect of age on any of the hematologic markers. In practical terms, this means that age is not predictive of blood-marker level; rather, knowing baseline blood-marker level and collection time of baseline can help predict current blood-marker levels.
Costongs et al 2 studied the variation of blood cells and the differential leukocyte count during a period of 6 months (month to month); the 6-month CV I that they reported was lower by approximately 50%, compared with our data. Fraser et al 17 studied the biological variation of common hematologic markers in healthy elderly adults (age 70 years or older) for a period of 20 weeks; their subjects had lower CV I and higher CV G values (with the exception of monocytes), compared with our data. These differences may be due to the variability of sex and ethnicity, along with shorter follow-up versus white non-Hispanic men and longer follow-up and more data points than in our study. Hematological markers showed significant individuality; as a consequence, the conventional population-based reference values are of limited usefulness. Also, screening using reference limits will not detect latent or early diseases in many subjects. 17 The limitation of the II on population-based reference values is restricted to a situation in which a conclusion is drawn based on changes in a single sample. When the II is low, it is important to stratify the population, 18 to obtain a separate RI for subpopulations, and to collect data from specimens from the same individual. 19 When the laboratory values for a specimen are outside an RI and the result is verified by a repeat test, a high II has considerable influence on the repeated result, facilitating the decision-making process. However, a low II on repeated testing will be close to the original result and give no new information.
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Conclusions
We observed a decline in RBC, Hg (g/dL), Hct (%), WBC, neutrophil counts, and PLT and a corresponding increase in MCV (fL), MCH (pg), and monocyte counts; no statistically significant changes were observed in MCHC (g/dL) and lymphocyte counts during the 30 years in which we followed up with the cohort individuals ( Table 2 ). The percentage of CV I of RBC, MCV, MCH, WBC, lymphocytes (except in the first year), and PLT were smaller than the percentage of CV G ; CV I was greater than CV G in Hg (except at the 20-year mark, at which it was the same and bigger at 30 year mark), Hct, MCHC, monocytes (except in the first year), and neutrophils (except in the first year) ( Table 1) .
The conventional population-based reference value has its own problems. Blood cells and markers are not always constants that can be measured once in a single reference sample group and made applicable in all situations. Inherent biological variation (BV) affects all biomarkers tested in clinical laboratories and must be taken into consideration in the generation and application of reference values. 
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